Close the “Evidence Gap” in Your Formulary Management

Harness the power of Real-World Evidence (RWE) to build a precision formulary

And reduce the total cost of care while improving patient outcomes.

Man doing clinical research on a tablet

Rising healthcare expenditures are a constant pressure.

Through formulary management, pharmacy and therapeutics (P&T) committees are tasked with managing medication spending, which accounts for nearly 10% of overall healthcare costs.

Traditional formulary management processes and tools, however, are incomplete. Decisions often depend on evidence from randomized controlled trials (RCTs)—studies whose strict inclusion and exclusion criteria fail to represent the heterogeneous mix of real-world patients with multiple comorbidities, medication regimens, and more. This “evidence gap” can lead to suboptimal formulary designs that impact both your budget and patient care.

Real-world evidence (RWE), insights through analysis of real-world data (RWD)–which consists of electronic health records (EHR), labs, and other sources of deidentified patient health data–provides a solution to close this “evidence gap”.

 

Transform your formulary with timely, relevant, real-world evidence.

Discover how RWE uncovers biosimilars for autoimmune conditions that can deliver comparable health outcomes, presenting a potential $10,000 to $20,000 annual savings opportunity per patient.

See the RWE analysis comparing treatments for post-operative ileus, which found the less expensive option performed better, reducing 30-day readmissions and saving one health system over $2,000 per patient.

Learn how to identify the specific patient subpopulations that benefit most from costly medications like GLP-1s, justifying the investment by offsetting it with measurable reductions in inpatient costs.

Download the white paper to see how RWE can drive your next P&T committee meeting.

In the white paper you will learn how RWE can:

  • Unlock substantial savings on high-spend biologics
  • Optimize peri/post-procedural care and costs
  • Target high-cost therapies with precision

Download the white paper to see how RWE can drive your next P&T committee meeting.